Table 1.
Antimicrobial Susceptibility to C/T, IMI/REL, and Comparators Among P. aeruginosa With Nonsusceptible Phenotypes
| % Susceptible | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Phenotype/Ward Type, No. | Ceftolozane/ Tazobactam | Imipenem/Relebactam | Imipenem | Meropenem | Cefepime | Ceftazidime | Piperacillin/Tazobactam | Aztreonam | Levofloxacin | Amikacin |
| Meropenem-NS | ||||||||||
| ICU (207) | 83.1 | 68.1 | 4.4 | 0.0 | 45.9 | 47.8a | 36.2 | 26.1 | 27.1 | 90.8 |
| Non-ICU (208) | 88.9 | 72.6 | 9.6 | 0.0 | 48.6 | 59.1a | 44.2 | 31.3 | 29.3 | 92.3 |
| Piperacillin/tazobactam-NS | ||||||||||
| ICU (228) | 82.5 | 77.2 | 39.9 | 42.1 | 26.8 | 20.2a | 0.0 | 7.9a | 34.2 | 91.7 |
| Non-ICU (214) | 87.4 | 79.4 | 47.7 | 45.8 | 34.6 | 31.3a | 0.0 | 15.9a | 32.7 | 92.5 |
| Cefepime-NS | ||||||||||
| ICU (176) | 76.7 | 72.2 | 34.7 | 36.4 | 0.0 | 11.9a | 5.1 a | 4.6a | 30.7 | 89.2 |
| Non-ICU (179) | 84.4 | 77.1 | 38.6 | 40.2 | 0.0 | 30.2a | 21.8 a | 18.4a | 27.4 | 87.2 |
| Ceftazidime-NS | ||||||||||
| ICU (197) | 78.2 | 79.2 | 41.1 | 45.2 | 21.3 | 0.0 | 7.6 | 9.6 | 38.1 | 90.4 |
| Non-ICU (166) | 81.3 | 83.7 | 45.8 | 48.8 | 24.7 | 0.0 | 11.5 | 12.1 | 33.1 | 90.4 |
| Imipenem-NS | ||||||||||
| ICU (264) | 87.1a | 75.0 | 0.0 | 25.0a | 56.4 | 56.1a | 48.1a | 40.2a | 36.0 | 92.1 |
| Non-ICU (282) | 92.2a | 79.4 | 0.0 | 33.3a | 61.0 | 68.1a | 60.3a | 50.4a | 40.8 | 92.2 |
| MDR | ||||||||||
| ICU (140) | 71.4 | 65.7 | 15.7 | 18.6 | 11.4 | 15.7 | 5.7 | 2.9 | 17.9 | 84.3 |
| Non-ICU (114) | 77.2 | 67.5 | 17.5 | 18.4 | 12.3 | 19.3 | 10.5 | 4.4 | 14.0 | 83.3 |
| Pan-β-lactam-NS | ||||||||||
| ICU (90) | 65.6 | 56.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 15.6 | 86.7 |
| Non-ICU (65) | 72.3 | 63.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 10.8 | 84.6 |
| DTR | ||||||||||
| ICU (72) | 61.1 | 54.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 83.3 |
| Non-ICU (56) | 69.6 | 57.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 82.1 |
| IMI/REL-NS | ||||||||||
| ICU (66) | 72.7 | 0.0 | 0.0 | 0.0 | 25.8 | 37.9 | 21.2 | 13.6 | 15.2 | 80.3 |
| Non-ICU (59) | 78.0 | 0.0 | 1.7b | 3.4 | 30.5 | 54.2 | 25.4 | 17.0 | 11.9 | 81.4 |
| C/T-NS | ||||||||||
| ICU (43) | 0.0 | 58.1 | 20.9 | 18.6 | 4.7 | 0.0 | 7.0 | 4.7 | 18.6 | 67.4 |
| Non-ICU (32) | 0.0 | 59.4 | 31.3 | 28.1 | 12.5 | 3.1 | 15.6 | 6.3 | 9.4 | 71.9 |
Abbreviations: C/T, ceftolozane/tazobactam; DTR, difficult-to-treat resistance; ICU, intensive care unit; IMI/REL, imipenem/relebactam; MDR, multidrug-resistant; MIC, minimum inhibitory concentration; NS, nonsusceptible (intermediate or resistant MICs).
aStatistically significant difference between isolates from ICUs and non-ICU wards (P < .05).
bOne isolate tested with an IMI/REL MIC of 4 µg/mL (intermediate) and an IMI MIC of 2 µg/mL (susceptible).